AstraZeneca (LON:AZN) had its price target increased by Credit Suisse Group from GBX 8,200 ($107.87) to GBX 8,500 ($111.81) in a report published on Thursday morning, Borsen Zeitung reports. Credit Suisse Group currently has an outperform rating on the biopharmaceutical company’s stock.
Other research analysts have also recently issued research reports about the stock. Goldman Sachs Group set a GBX 5,500 ($72.35) target price on shares of AstraZeneca and gave the stock a sell rating in a report on Wednesday, October 30th. Citigroup reaffirmed a buy rating on shares of AstraZeneca in a research report on Thursday, November 7th. Bank of America reiterated a buy rating and issued a GBX 8,500 ($111.81) price target on shares of AstraZeneca in a research note on Tuesday, October 8th. Bryan, Garnier & Co reissued a buy rating on shares of AstraZeneca in a research report on Thursday, December 19th. Finally, Shore Capital reissued a buy rating on shares of AstraZeneca in a research report on Monday, January 13th. Three research analysts have rated the stock with a sell rating, two have given a hold rating and eleven have issued a buy rating to the stock. The company currently has an average rating of Buy and a consensus target price of GBX 7,831.07 ($103.01).
LON AZN opened at GBX 7,878 ($103.63) on Thursday. The company has a quick ratio of 0.70, a current ratio of 0.92 and a debt-to-equity ratio of 148.59. AstraZeneca has a 12-month low of GBX 109.51 ($1.44) and a 12-month high of £727.50 ($956.99). The company has a market capitalization of $103.37 billion and a PE ratio of 49.42. The firm’s 50 day moving average is GBX 7,551.12 and its 200-day moving average is GBX 7,171.69.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Recommended Story: How much money do you need to begin day trading?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.